Ligand Pharmaceuticals Incorporated (LGND)
Market Cap | 1.52B |
Revenue (ttm) | 118.31M |
Net Income (ttm) | 96.34M |
Shares Out | 17.96M |
EPS (ttm) | 5.32 |
PE Ratio | 15.94 |
Forward PE | 18.48 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 115,722 |
Open | 84.85 |
Previous Close | 84.85 |
Day's Range | 84.04 - 85.61 |
52-Week Range | 49.24 - 94.57 |
Beta | 0.92 |
Analysts | Strong Buy |
Price Target | 116.33 (+37.2%) |
Earnings Date | Aug 6, 2024 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $116.33, which is an increase of 37.20% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/b/t/press1-2499596.jpg)
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration (...
![](https://cdn.snapi.dev/images/v1/a/g/press2-2484186.jpg)
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as MSD outside the United States and Canada, has received approval...
![](https://cdn.snapi.dev/images/v1/6/l/conf9-2446530.jpg)
Ligand to Participate in Upcoming Investor Conferences
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Todd Davis (Chief Executive Officer) and Tavo Espinoza (Chief Financial Officer) will participat...
![](https://cdn.snapi.dev/images/v1/p/7/press8-2416077.jpg)
Ligand Reports First Quarter 2024 Financial Results
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and bu...
![](https://cdn.snapi.dev/images/v1/d/g/press13-2414360.jpg)
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
JUPITER, Fla. and LEXINGTON, Mass.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agent...
![](https://cdn.snapi.dev/images/v1/u/p/conf6-2385295.jpg)
Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial market...
![](https://cdn.snapi.dev/images/v1/o/z/press4-2360831.jpg)
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
LONDON--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on ...
![](https://cdn.snapi.dev/images/v1/d/m/press5-2354293.jpg)
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
JUPITER, Fla. & DURHAM, N.C.--(BUSINESS WIRE)--Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of s...
![](https://cdn.snapi.dev/images/v1/o/f/conf3-2309543.jpg)
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a f...
![](https://cdn.snapi.dev/images/v1/4/s/press5-2306095.jpg)
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand's Human Capital Management and Compensation Committee approved the g...
![](https://cdn.snapi.dev/images/v1/d/2/press7-2295446.jpg)
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forec...
![](https://cdn.snapi.dev/images/v1/r/s/press2-2289683.jpg)
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japan...
![](https://cdn.snapi.dev/images/v1/g/w/press18-2280256.jpg)
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen ...
![](https://cdn.snapi.dev/images/v1/o/t/conf13-2274460.jpg)
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. fi...
![](https://cdn.snapi.dev/images/v1/b/c/press16-2270967.jpg)
Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, today announced the publication of research in...
![](https://cdn.snapi.dev/images/v1/n/f/biotech3-2218898.jpg)
Ligand Pharma's at-home skin treatment gets FDA approval
Ligand Pharmaceuticals' topical treatment for a viral skin infection has received approval from the U.S. health regulator, the company said on Friday, marking the first-ever at-home approved treatment...
![](https://cdn.snapi.dev/images/v1/c/t/press4-2218859.jpg)
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) f...
![](https://cdn.snapi.dev/images/v1/a/6/im-09753645size1777777777777778width800-2208256.jpg)
20 favorite small-cap stocks for 2024 among Wall Street analysts
The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...
![](https://cdn.snapi.dev/images/v1/i/6/press2-2193353.jpg)
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand's senior ma...
![](https://cdn.snapi.dev/images/v1/u/0/press10-2186481.jpg)
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. Members of Ligand's senior management team will pro...
![](https://cdn.snapi.dev/images/v1/9/u/press13-2147997.jpg)
Ligand Reports Third Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand reports third quarter 2023 financial results.
![](https://cdn.snapi.dev/images/v1/p/r/press8-2132839.jpg)
Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million
SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million.
![](https://cdn.snapi.dev/images/v1/f/w/conf16-2120906.jpg)
Ligand To Report Third Quarter 2023 Financial Results On November 8
SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand To Report Third Quarter 2023 Financial Results On November 8.
![](https://cdn.snapi.dev/images/v1/l/h/press13-2079828.jpg)
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Assets of Novan, Inc. for $12.2 Million.
![](https://cdn.snapi.dev/images/v1/q/o/press3-2078931.jpg)
Ligand Appoints Martine Zimmermann to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Ligand Appoints Martine Zimmermann to its Board of Directors.